Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-FBP8 PET for Brain Fibrin in ADRD
NCT05336695Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2022
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Massachusetts General Hospital. Primary endpoint: Concentration of fibrin in the brains of ADRD subjects and healthy controls. Started Mar 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05336695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336695.